title: Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid.
abstract: Isoniazid and pyrazinamide are well-known hepatotoxic drugs, often used in combination. The aim of this study was to assess the prognostic influence of pyrazinamide on the outcome of fulminant or subfulminant liver failure caused by antituberculous therapy. Eighteen patients with fulminant or subfulminant liver failure due to antituberculous therapy were studied. Nine patients received isoniazid and rifampicin without pyrazinamide (group 1), and nine patients received isoniazid and rifampicin together with pyrazinamide (group 2). The severity of fulminant and subfulminant liver failure, as judged by the prevalence of coma and the lowest level of factor V, was similar in the two groups. Spontaneous survival was greater in group 1 (eight of nine) than in group 2 (two of nine) (P < .02). The authors conclude that pyrazinamide co-administration was associated with an increased mortality in patients with fulminant or subfulminant hepatitis occurring during antituberculous therapy. In these patients, pyrazinamide administration and an interval of more than 15 days between the onset of antituberculous treatment and jaundice, combined with grade III encephalopathy and factor V below 20%, predicted death without liver transplantation.
authors.affiliation: Service d'Hépatologie et INSERM U24, Hôpital Beaujon, Clichy, France.
authors.forename: F
authors.initials: F
authors.lastname: Durand
authors.forename: J
authors.initials: J
authors.lastname: Bernuau
authors.forename: D
authors.initials: D
authors.lastname: Pessayre
authors.forename: D
authors.initials: D
authors.lastname: Samuel
authors.forename: J
authors.initials: J
authors.lastname: Belaiche
authors.forename: C
authors.initials: C
authors.lastname: Degott
authors.forename: H
authors.initials: H
authors.lastname: Bismuth
authors.forename: J
authors.initials: J
authors.lastname: Belghiti
authors.forename: S
authors.initials: S
authors.lastname: Erlinger
authors.forename: B
authors.initials: B
authors.lastname: Rueff
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D006501:Hepatic Encephalopathy / Q000139:chemically induced* / Q000401:mortality; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000009:adverse effects*; D012293:Rifampin / Q000009:adverse effects; D015996:Survival Rate
chemical_list: D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin